Fresenius Shares: Strong Operational Performance Contrasts with Market Valuation

The healthcare conglomerate Fresenius has reported a robust finish to its 2025 fiscal year, marked by significant profit growth. Despite this operational strength, the company’s stock performance has notably lagged behind its fundamental progress, creating a divergence that has captured market attention.

Confirmed Targets for the Coming Year

Management has reaffirmed a positive outlook for the current period. The group is targeting organic revenue growth in a range of 4 to 7 percent. Furthermore, currency-adjusted earnings per share, excluding the stake in Fresenius Medical Care, are projected to increase by 5 to 10 percent. This forecast serves as a key operational benchmark for the 2026 financial year as the company’s broader transformation continues to advance.

Core Divisions Drive Profitability Expansion

A pronounced improvement in efficiency characterized the past year. Group revenue advanced organically by 7 percent to reach €22.554 billion. A key metric, core earnings per share, which excludes the contribution from Fresenius Medical Care, climbed 12 percent to €2.87.

Should investors sell immediately? Or is it worth buying Fresenius?

This performance was primarily fueled by the Kabi and Helios divisions. By concentrating on biopharmaceuticals and medical technology, Fresenius Kabi elevated its EBIT margin to 16.4 percent. The hospital operator Helios also demonstrated stable growth, reinforcing its status as Europe’s leading private healthcare service provider.

Market Performance Lags Fundamentals

The operational momentum has, so far, failed to translate into corresponding share price appreciation. Currently trading at €43.75, the equity is quoted approximately 9 percent below its 50-day moving average. Over a 30-day horizon, the stock has registered a decline of over 14 percent, a trend that stands in stark contrast to the confirmed growth rates.

CEO Michael Sen continues to emphasize the strategic focus on digitizing clinical processes and expanding growth segments within Fresenius Kabi. The overarching corporate strategy aims to further reduce organizational complexity and ensure sustainable profitability for the long term.